Original Research Article

An open labeled, randomized, controlled clinical study to evaluate the efficacy of Torchnil capsules and Febcin tablet as add-on therapy for Covid-19 patients

Renuka Munshi *, Dipti Kumbhara, Pranesh Pawaskara, Girish Rajadakshyab, H.S. Palep c

a Department of Clinical Pharmacology, TN Medical College & BYL Nair Hospital, Mumbai Central, Mumbai, Maharashtra 400008, India
b Department of Medicine, TN Medical College & BYL Nair Hospital, Mumbai Central, Mumbai, Maharashtra 400008, India
c Dr. Palep's Medical Research Foundation Private Limited, Lower Parel West, Mumbai, Maharashtra 400013, India

A R T I C L E   I N F O

Article info
Article history:
Received 4 January 2022
Received in revised form
12 February 2022
Accepted 12 February 2022
Available online 24 February 2022

Keywords:
Covid-19
Cap. Torchnil
Tab. Febcin
Biomarkers
Oxygen requirements
Hospital stay

A B S T R A C T

Objectives: This study was conducted to evaluate the efficacy and safety of Cap. Torchnil & Tab. Febcin when given as add-on therapy to Covid19 positive patients with moderate disease.

Material and methods: Following written informed consent, patients were randomized to receive Cap. Torchnil & Tab. Febcin in addition to standard of care (SOC) [Add-on Group] or only SOC [SOC Group] for 14 days. Effect on clinical symptoms, WHO Clinical Assessment scale, hospital stay duration, time to Covid negative report, Sp02 levels and biomarkers was assessed during admission and relapse rate, if any, post discharge for 3 months.

Results: 193 patients were screened and 150 completed the study, 77 in Add-on Group and 73 in SOC Group. Improvement in Covid related symptoms, WHO Assessment scale, time to Covid negative report, Sp02 levels and biomarkers was assessed during admission and relapse rate, if any, post discharge for 3 months.

Conclusion: The study results thus showed that Cap. Torchnil and Tab. Febcin were effective and safe when given as add-on therapy to SOC in the clinical management of patients with moderate Covid-19 disease.

© 2022 The Authors. Published by Elsevier B.V. on behalf of Institute of Transdisciplinary Health Sciences and Technology and World Ayurveda Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Coronavirus disease (Covid-19) is an infectious disease caused by the SARS-CoV-2 virus. The novel virus was first identified in the Chinese city of Wuhan in December 2019 which then quickly spread around the World inspite of a lockdown. The World Health Organization (WHO) declared a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020 [1]. Since then, multiple variants of the virus have emerged and become dominant in many countries, with the Alpha, Beta, Gamma, Delta and Omicron variants being the most virulent [2]. As of 10 December 2021, 267,865,289 confirmed cases and 5,285,888 deaths have been reported from India [3].

The Covid-19 pandemic is unprecedented in several aspects and has challenged the health care system. Till date there is no specific treatment available for the disease. Covid-19 vaccines have been looked at to prevent disease severity [4,5]. However, the emergence of mutant and virulent strains of the virus can impose challenge to the efficaciousness of Covid-19 vaccines [6].

Different health systems are trying to find out new or repurposed drugs to treat Covid-19 infection [7]. D. Silveira et al. have reported that herbal medicines have better safety margin and enough efficacy to be used as adjuvant in Covid-19 [8]. Certain compounds like Curcumin have been postulated to be effective in Covid-19 treatment due to its antiviral and anti-inflammatory...
properties and its action at different levels of the viral infection [9]. Vigorous efforts are also being taken by the Department of AYUSH to find an effective herbal Ayurvedic intervention for both prophylaxis and therapeutic management.

Cap. Torchnil and Tab. Febcin are 2 polyherbal proprietary medicines marketed by Dr. Palep’s Medical Research Foundation. Cap. Torchnil has been in use for more than two decades to successfully treat recurrent pregnancy loss due TORCH infections and unknown etiology [10]. Cap. Torchnil has been shown to inhibit the HIV Reverse transcriptase (RT) enzyme and P24 antigen in vitro and the activity of the herbal constituents were comparable with that of AZT and Lamivudine [10]. Tab. Febcin contains ingredients which are known to possess anti-inflammatory, immunomodulatory, antioxidant and antimicrobial (bacteria & viruses) properties. In silico docking studies of different ingredients of Cap. Torchnil & Tab. Febcin were carried out against the corona spike protein to evaluate their ability to inhibit the active proteins. The results showed that most of the ingredients bound to the spike proteins of Covid-19 thus indicating that they could be used as treatment against the Corona virus (data on file).

The present study was thus aimed to assess the efficacy and safety of these 2 AYUSH interventions (Cap. Torchnil + Tab. Febcin) when given as add-on therapy in the clinical management of Covid-19 positive patients with moderate Covid-19 disease.

2. Methods

2.1. Study design

This open-labeled, randomized, controlled, comparative, proof of concept, single center clinical trial was conducted after receiving Institutional Ethics Committee approval (IEC/135/2020). The study was registered in the Clinical Trial Registry of India – CTRI number REF/2021/09/047694. The study was conducted in compliance with the Indian Good Clinical Practice (GCP), guidelines, Declaration of Helsinki concerning medical research in humans (Revised Seoul, 2008) and ‘Ethical Guidelines for Biomedical Research on Human Subjects’ issued by Indian Council of Medical Research, 2017. The study was in compliance with updated CONSORT [2010] reporting guidelines.

Adult patients between 18 and 70 years of age, proven to be positive for SARS-CoV-2 infection, as confirmed by the RT-PCR test 48 h prior to the entry into the study and were admitted with moderate Covid-19 (as per MOFHW criteria) [11] for treatment at this open-labeled, randomized, controlled, comparative, proof of concept, single center clinical trial was conducted after receiving Institutional Ethics Committee approval (IEC/135/2020). The study was registered in the Clinical Trial Registry of India – CTRI number REF/2021/09/047694. The study was conducted in compliance with the Indian Good Clinical Practice (GCP), guidelines, Declaration of Helsinki concerning medical research in humans (Revised Seoul, 2008) and ‘Ethical Guidelines for Biomedical Research on Human Subjects’ issued by Indian Council of Medical Research, 2017. The study was in compliance with updated CONSORT [2010] reporting guidelines.

Adult patients between 18 and 70 years of age, proven to be positive for SARS-CoV-2 infection, as confirmed by the RT-PCR test 48 h prior to the entry into the study and were admitted with moderate Covid-19 (as per MOFHW criteria) [11] for treatment at

2.2. Drug details

The constituents of the study medications are as follows:

Each Capsule of Torchnil contains Glycyrrhiza glabra (Yashtimadhu), Tinospora cordifolia (Guduchi), Solanum indicus (Ringinul), Piper longum (Lendi Pimpli), Tribulis terrestris (Gokshuru), Clerodendrum serratum (Bharang-Mul), Punica granatum (Dadim), Vanda roxburghii (Rasna), Rubia cordifolia (Manjistha), Solanum xanthocarpum (Kantakari) and Andropogon muricatus (vala).

Each Tablet of Febcin contains Cyperus rotudus (Musta), Fumaria parviflora (Parpataka), Fagonia Arabica (Duralabha), Tinospora cordifolia (Guduchi), Ginger officinalis (Shrunthi), Cocculus hirsutus (Laghapushta), Glycyrrhiza glabra (Yashtimadhu) and Andropogon muricatus (Vala/Usheer).

The details of the role of each plant as per Ayurvedic textbooks with their quantity in the study drugs along with the package insert of the study drugs is appended as Appendix 1.

The study medications were given only for 14 days, however the patients were monitored and followed up for a period of 3 months, i.e. 2½ months post stopping of treatment. Following discharge, the patients were requested to follow-up either physically or telephonically every 15 days till the end of the study. At every physical visit, the patients’ vital signs and clinical examination was conducted and SpO2 levels were monitored. In case they had any symptoms suggestive of a repeat Covid infection, like fever, sore throat, cough, loss of taste and/or smell etc, an RT-PCR was done to rule out Covid 19 infection.

3. Objectives

3.1. Primary study objectives

To confirm the efficacy of 2 Ayush interventions (Cap. Torchnil + Tab. Febcin) prescribed as add-on therapy in improving the clinical symptoms, reducing the duration to RT-PCR negative reports and confirming safety in patients with Covid-19 moderate disease.

3.2. Secondary study objectives

To confirm the efficacy of two Ayush interventions (Cap. Torchnil + Tab. Febcin) when given add-on therapy in decreasing based on Covid-19 disease pathogenesis. These medications were in addition to the standard of care (SOC) treatment given to all patients with moderate Covid-19 infection. Patients in the SOC Group received only Standard of Care treatment given to all patients with moderate infection, the details of which were as follows:

- Symptomatic treatment (paracetamol, levocetrizine/other anti-histaminics, Condy’s gargles).
- Tab. azithromycin 500 mg OD × 3–5 days
- Inj remdesivir – IV loading dose of 200 mg on day 1, followed by 100 mg daily IV for 4 days (total 5 days)
- Tab. hydroxychloroquine 400 mg bd on Day 1, then 400 mg OD for 5 days (ECG to be monitored for QT prolongation, especially in the presence of other agents causing the same) (chloroquine 500 mg bd may be used if HCQs not available)
- Tab Ivermectin 12 mg single dose
- Antiemetics, proton pump inhibitors and probiotics as indicated
- Supportive treatment as indicated
the need for oxygen supplementation and hospital stay in patients with Covid-19 moderate disease.

4. Statistical considerations

4.1. Sample size

Assuming a 15% difference between the AYUSH Interventions + SOC Group & the SOC alone group based on previous data wherein \textit{in vitro} evaluation of anti-HIV reverse transcriptase activity of Cap. Torchnil, showed that one of the constituents, \textit{S. xanthocarpum} (Kantakari) gave the highest inhibition of about 37\%, followed by \textit{P. granatum} (Pomegranate), −34\% inhibition when compared to AZT (15\%). Keeping the power at 80\%, the significance level at 5\% & the superiority margin (\(\delta\)) at 7\%, the sample size came to 140 completed cases with 70 cases in each group. Keeping the dropout rate at 10\%, the sample size was estimated to 154 cases with 77 cases in each group.

4.2. Statistical analysis

Statistical analysis was done using ANOVA followed by posthoc tests for the parametric data and Kruskal Wallis test for non-parametric data. The level of significance for all analysis was taken as \(p<0.05\).

5. Study outcomes

The study Outcome measures that were assessed during the study were as follows:

5.1. Primary outcomes

To assess the proportion of patients who became clinically asymptomatic, Covid RT-PCR test negative and those who worsened to severe stage of the disease during the hospital stay.

5.2. Secondary outcomes

To determine the changes in Covid associated serum biomarker levels, oxygen requirement from baseline to discharge and decrease in the duration of hospital stay.

5.3. Assessment parameters

The following parameters were assessed during the study:

1. Clinical COVID19 related symptoms
2. WHO Clinical assessment scale (from enrollment to discharge)
3. RT-PCR reports
4. Duration of hospital stay
5. Biomarkers: CRP, CPK, IL6, LDH, Ferritin, D-dimer (from enrollment to discharge)
6. Assessment of safety: hematological and biochemical reports and clinical adverse events.

6. Results

Following ethical approval, the study was conducted over a period of 9 months from October 2020 to June 2021. 193 patients with moderate Covid-19 disease were assessed for eligibility, of

![ Consort Flow Chart ](https://example.com/consort-flow-chart.png)
which 160 patients with moderate Covid-19 disease were enrolled in the study. 80 patients each were allocated to one of the 2 study groups. From the Add-on Group, 2 patients withdrew from the study while in hospital due to adverse effects of the study medications. Post discharge, 77 participants completed the study while 3 patients dropped out of the study. From the SOC Group, 73 participants completed the study and 7 participants dropped out of the study. Fig. 1 gives the study flowchart of the status of enrolled patients.

6.1. Demographic & co-morbid conditions details

The demographic details of the study participants showed that the average age of the study patients ranged from 43 to 63 years and that there was a similar distribution of men and women in both the study groups. Majority of the study patients also had underlying medical conditions like controlled type 2 Diabetes mellitus, hypertension or a combination of both. The details are given in Table 1 below.

6.2. Change in Covid-19 related clinical symptoms

At admission, most patients clinically had symptoms like fever, sore throat, difficulty in breathing, dry cough, nasal discharge, headache, loss of taste and/or smell, generalized weakness and GIT symptoms. The change in these symptoms were assessed for a period of 3 months on days 1, 7, 14, 30, 45, 60, 75 and 90. Clinically the symptoms were assessed as “present” OR “absent” over the period of 3 months. As can be seen in Table 2 below, majority of the symptoms resolved or improved earlier in the Add-on Group as compared to the SOC Group. The quicker recovery was statistically significant with regard to symptoms of headache and dry cough.

6.3. WHO Clinical Assessment scale

As seen in Table 3, clinical improvement as per the WHO Clinical Assessment scale was seen in both the study groups, however the improvement was observed to be fast in in the Add-on Group (Day 7) as compared to the SOC Group with regard to decreased oxygen

| Table 1 | Demographic details & co-morbid medical conditions of the study patients. |
|---------|-------------------------------------------------|
|         | Add-on Group (n=80) | SOC Group (n=80) |
| Age (in years) expressed as median [with range] | 53.5 [28–78] | 55 [31–72] |
| Gender n (%) | Males: 55 (74.03%) | Males: 49 (63.64%) |
| Females: 20 (25.97%) | Females: 28 (36.36%) |
| No co-morbid conditions | 22 (27.5%) | 17 (21.25%) |
| Type 2 Diabetes mellitus (T2DM) | 32 (40%) | 35 (43.75%) |
| Hypertension (HT) | 21 (26.25%) | 25 (31.25%) |
| T2DM + HT | 17 (21.25%) | 21 (26.25%) |
| Bronchial asthma | 5 (6.25%) | 3 (3.75%) |

| Table 2 | Number of patients reporting a change in Covid-19 related clinical symptoms. |
|---------|-------------------------------------------------|
|         | Baseline | Day 7 | Day 14 | Day 30 | Day 45 | Day 60 | Day 75 | Day 90 |
| Fever | Add-on Group (n = 77) | 43 | 0** | 0** | 0* | 0* | 0* | 0* | 0* |
| SOC Group (n = 73) | 55 | 11* | 4* | 0* | 0* | 0* | 0* | 0* |
| Sore throat | Add-on Group (n = 77) | 10 | 0** | 0** | 0* | 0* | 0* | 0* | 0* |
| SOC Group (n = 73) | 15 | 7 | 2** | 4* | 2** | 0** | 0* | 0* | 0* |
| Difficulty in breathing | Add-on Group (n = 77) | 64 | 49 | 18*** | 10*** | 5*** | 0*** | 0*** | 0*** |
| SOC Group (n = 73) | 70 | 49* | 19*** | 10*** | 7*** | 0*** | 0*** | 0*** | 0*** |
| Dry cough | Add-on Group (n = 77) | 52 | 24** | 9*** | 3*** | 0*** | 0*** | 0*** | 0*** |
| SOC Group (n = 73) | 56 | 37** | 18*** | 7** | 3** | 0** | 0* | 0* | 0* |
| Nasal discharge | Add-on Group (n = 77) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SOC Group (n = 73) | 6 | 2** | 0** | 0* | 0* | 0* | 0* | 0* | 0* |
| Headache | Add-on Group (n = 77) | 40 | 24 | 20 | 18 | 15 | 12 | 7* | 5** |
| SOC Group (n = 73) | 45 | 40** | 32* | 26** | 23** | 20** | 15* | 13** | 5** |
| Loss of taste | Add-on Group (n = 77) | 9 | 2 | 0 | 0 | 0 | 0 | 0*** | 0*** |
| SOC Group (n = 73) | 12 | 4 | 2 | 0* | 0* | 0* | 0* | 0* | 0* |
| Loss of smell | Add-on Group (n = 77) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SOC Group (n = 73) | 4 | 0* | 0* | 0* | 0* | 0* | 0* | 0* | 0* |
| Generalized weakness | Add-on Group (n = 77) | 56 | 56 | 54 | 51 | 50 | 46 | 39 | 35** |
| SOC Group (n = 73) | 58 | 55 | 52 | 43 | 40 | 38* | 35** | 35** | 35** |
| G1T symptoms | Add-on Group (n = 77) | 21 | 11 | 5 | 0 | 0*** | 0*** | 0*** | 0*** |
| SOC Group (n = 73) | 25 | 18 | 11 | 7* | 5** | 3*** | 0*** | 0*** | 0*** |

*p<0.01, **p<0.001 as compared to Day 1 using Kruskal Wallis test.

#p<0.05, ##p<0.01, ###p<0.001 as compared to Day 7 using Kruskal Wallis test.

##p<0.001 as compared to Day 14 using Kruskal Wallis test.

$**p<0.01$ as compared to Day 1 using unpaired t test with Welch correction.

$**p<0.05$ as compared to Add-on Group using unpaired t test with Welch correction.
condition during the hospital stay and there were no deaths re-

6.5. Number of days wherein patients became covid negative

It was observed that patients who received the study medica-
tions became Covid negative earlier than those on SOC treatment. The mean duration for the RT-PCR negative report (COVID negative status) was 9.51 ± 1.55 days in the Add-on Group as compared to 10.89 ± 1.74 days for the SOC Group.

None of the study patients had a worsening of their clinical condition during the hospital stay and there were no deaths reported during the study period.

6.6. Effect on serum biomarkers levels

As seen from Table 5, an improvement in the serum biomarker levels was seen in both groups with a greater fall observed in the Add-on group. The fall in CPK, D-dimer and IL-6 values at Day 14 was statistically significant as compared to the SOC Group whereas the fall in LDH levels was statistically significant at Days 7 & 14 in the Add-on group.

6.7. Change in the requirement for supplemental oxygen

It was observed that the average percentage of oxygen in the blood (SpO2) and oxygen requirements of the study patients improved during their hospital stay in both groups with the improvement seen earlier in the Add-on group though not statistically significant. The results are presented in Table 6.

6.8. Mean duration of hospital stay

Patients in the Add-on group recovered faster and were discharged earlier as compared to the SOC Group, though the difference was not statistically significant. The mean duration of hospital stay for the Add-on group was 11.4 days as compared to the SOC Group (13.4 days).

6.9. Safety evaluation

Safety was monitored by clinical assessment and laboratory investigations. 2 patients from the Add-on group refused further participation in the study due to complaints of hyperacidity after starting the IP. No major changes were observed in the laboratory safety parameters in both the groups.

6.10. Follow up assessment

Following discharge, all the study patients were requested to follow up for a period of 2½ months to monitor their clinical condition and document any relapse or worsening of their Covid state. The patients followed up either physically or telephonically every 15 days till the end of the study. Of the 158 patients, 1 patient from the Add-on group and 7 patients from the SOC Group were lost to follow-up post discharge as they went to their native place and were uncontactable inspite of repeated attempts to call them. Of the 150 patients who followed up, 49 patients from the Add-on group came for physical visits while 28 patients preferred

| Day 0 | Day 3 | Day 7 | Day 10 | Day 14 |
|-------|-------|-------|--------|--------|
| Add-on Group (n = 78) | 4.04 ± 0.52 | 3.88 ± 0.46 | 3.35 ± 0.53 | 3.26 ± 0.47 | 3.0 ± 0.5 |
| SOC Group (n = 80) | 4.04 ± 0.47 | 3.88 ± 0.46 | 3.74 ± 0.5 | 3.39 ± 0.52 | 3.42 ± 0.5 |

**p<0.01, ***p<0.001, as compared to Day 1 using Friedman test (nonparametric repeated measures ANOVA).

#p<0.05, ##p<0.001, as compared to Day 3 using Friedman test (nonparametric repeated measures ANOVA).

###p<0.001 as compared to Day 7 using Friedman test (nonparametric repeated measures ANOVA).

####p<0.001 as compared to Day 10 using Friedman test (nonparametric repeated measures ANOVA).

*```
telephonic visits. In case of the SOC Group, 42 patients came for physical visits while 31 patients preferred telephonic visits. At every physical visit, the patients’ vital signs and clinical examination was conducted and SpO2 levels were monitored, and RT-PCR done in case there were symptoms suggestive of a Covid infection.

All 91 patients who came for the physical visit were clinically stable with no worsening of their clinical condition and no signs or symptoms suggestive of a repeat Covid infection. Their vital signs and SpO2 levels were within the normal range in both groups although the decrease in the pulse and respiratory rate at days 75 & 90 was statistically significant in the Add-on group as compared to the SOC Group (refer Table 7).

7. Discussion

Medicines from natural sources have always been intriguing to researchers to develop novel drug candidates and/or molecules especially for the treatment of diseases that have no cure in modern medicine. Covid-19 caused by the novel coronavirus (SARS-CoV-2) is one such infectious disease for which no specific drug or vaccine is available, yet. Historically, natural products and herbal medicines have been used for the prevention of viral infections and generally show favorable efficacy and acceptable toxicity. Thus, since the Covid-19 pandemic outbreak, various herbal medicines have been used for the prevention and treatment of the infection [12].

In our study, we evaluated the effect of 2 polyherbal proprietary medicines, Cap. Torchnil and Tab. Febcin containing a combination of different medicinal plants for their efficacy in the clinical management of Covid-19 positive hospitalized patients with moderate disease in addition to standard of care. The effects of these 2 medications were compared to that of standard therapy offered to these patients.

Of the 160 patients with Covid-19 infection of moderate severity included in the study, 150 completed the study duration. All these patients recovered from their illness while in hospital and were discharged with no deaths. Patients receiving the study medications showed a faster recovery with regard to their clinical symptoms with statistically significant improvement seen with regard to headache and dry cough. Symptoms such as fever and sore throat resolved within 7 days in the study group as compared to the Control group. This is possibly because of the anti-pyretic effects of Tab. Febcin which has been proven in a rat model wherein significant antipyretic action was observed as compared to paracetamol [13]. The mean SpO2% levels indicated an improvement from Day 1 onwards decreasing the requirement for oxygen from Day 10 in patients in the study group as compared to the Control group. With respect to the serum biomarker levels, an improvement in all the biomarker levels was seen in patients in the study group with a significant improvement seen for CPK, LDH, D-dimer & IL-6 levels, indicating anti-inflammatory effect of the study medications. The mean hospital stay duration was 2 days shorter in the treatment group (11.40 vs.13.44 days) and as was the number of days to a RT-PCR Covid-19 negative report (9.51 days for the Treatment group compared to 10.89 days in the Control group). All the above effects demonstrate that the study medications had anti-inflammatory, antipyretic and possibly antiviral effect and/or immunomodulatory effect promoting an earlier recovery in patients who consumed the medications. Both

### Table 5
Effect of study medications on serum biomarkers levels.

| Sr. no. | Day 0 | Day 7 | Day 14 |
|---------|-------|-------|--------|
| CRP (mg/L) |       |       |        |
| 1 Add-on group (n = 78) | 40.65 ± 21.85 | 38.98 ± 25.55 | 37.76 ± 21.16 |
| 2 SOC Group (n = 80) | 40.74 ± 24.29 | 39.31 ± 22.35 | 40.71 ± 22.41 |
| CPK (U/L) |       |       |        |
| 1 Add-on group (n = 78) | 71.65 ± 49.57 | 68.75 ± 41.75 | 57.23 ± 38.75**##p |
| 2 SOC Group (n = 80) | 72.24 ± 43.71 | 68.98 ± 43.29 | 70.60 ± 42.91 |
| LDH (U/L) |       |       |        |
| 1 Add-on group (n = 78) | 229.06 ± 336.12 | 268.54 ± 250.50**##p | 666.68 ± 227.91**##p |
| 2 SOC Group (n = 80) | 277.98 ± 349.37 | 282.73 ± 316.90 | 767.56 ± 285.35 |
| Ferritin (ng/ml) |       |       |        |
| 1 Add-on group (n = 78) | 542.52 ± 269.62 | 463.66 ± 242.28** | 454.54 ± 242.56** |
| 2 SOC Group (n = 80) | 547.47 ± 328.45 | 499.93 ± 279.56 | 457.06 ± 278.51* |
| D-Dimer (µg/ml) |       |       |        |
| 1 Add-on group (n = 78) | 394.76 ± 343.21 | 325.77 ± 295.81** | 253.48 ± 242.09**##p |
| 2 SOC Group (n = 80) | 444.95 ± 295.13 | 399.57 ± 266.08 | 355.18 ± 245.53* |
| IL-6 (pg/ml) |       |       |        |
| 1 Add-on group (n = 78) | 118.64 ± 166.70 | 115.33 ± 169.68 | 85.18 ± 123.02**## |
| 2 SOC Group (n = 80) | 212.10 ± 263.47 | 168.46 ± 234.66 | 157.73 ± 189.64* |

*p<0.01 as compared to Day 7; **p<0.01 as compared to Day 1 (Within group).
*p<0.01; **p<0.001 as compared to Day 14 of SOC Group using Unpaired t test with Welch correction.
*p<0.001 as compared to Day 7 of SOC Group using unpaired t test with Welch correction.

### Table 6
Requirement of supplemental oxygen in both study groups.

| Add-on group (n = 78) | Day 0 | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | Day 9 | Day 10 | Day 14 |
|-----------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Average SpO2 | 91.36 ± 13.8 | 95.94 ± 2.18 | 96.52 ± 2.06 | 96.73 ± 1.73 | 98.75 ± 1.02 | 96.94 ± 1.22 | 97.08 ± 1.35 | 97.17 ± 1.01 | 97.23 ± 0.92 | 97.45 ± 0.94 |
| O2 requirement (L/min) | 7.90 ± 3.98 | 7.43 ± 4.32 | 6.53 ± 3.69 | 5.35 ± 2.98 | 5 ± 3.10 | 4.78 ± 3.20 | 3.69 ± 2.88 | 2.53 ± 2.66 | 1.64 ± 2.48 | 0 | |
| SOC Group (n = 80) | 91.43 ± 1.27 | 94.30 ± 1.05 | 95.50 ± 1.50 | 96.14 ± 1.07 | 96.38 ± 1.60 | 96.50 ± 1.85 | 96.62 ± 1.37 | 96.67 ± 1.22 | 96.82 ± 1.24 | 96.96 ± 1.12 | | |
| Average SpO2 | 91.36 ± 3.79 | 7.55 ± 4.21 | 6.91 ± 3.51 | 6.57 ± 3.50 | 6.47 ± 3.43 | 6.05 ± 3.21 | 5.53 ± 3.57 | 4.95 ± 3.52 | 4.55 ± 3.81 | 1.16 ± 1.51 | |
the study medications contain various medicinal plants that are known to have anti-inflammatory and immunomodulatory properties like Glycyrrhiza glabra, T. cordifolia, T. terrestris and C. serratum, plants like P. longum, S. indicus, Solanum xanthocarpus which are effective in respiratory illnesses and those with anti-inflammatory properties like F. parviflora, Fagonia arabica, C. hirsutus and A. muricatum. [14–18].

In-silico studies have also shown that the two formulations when evaluated against the corona viral membrane protein for their inhibiting ability of the active spike protein showed that there was interaction between the different constituents with the different regions of the spike protein suggesting that the formulations would be functionally significant against the corona viral protein. (Unpublished data). The results with these two herbal formulations are similar to those observed with other herbal drugs used to treat Covid-19 infection. AYUSH 64, which contains aqueous extracts of Alstonia scholaris (bark), Picrorhiza kurroa (rhizome), S. indicus, Solanum xanthocarpus and Caesalpinia cristata was found to hasten recovery, reduce hospitalization and improve overall health when given to patients suffering from mild and moderate symptomatic Covid-19 along with SOC [19]. In silico docking studies to assess the potential mechanism of action of AYUSH-64 compounds against Severe Acute Respiratory Syndrome-Corona Virus (SARS-CoV-2) Main Protease (Mpro; PDB ID: 6LU7) demonstrated that of the 36 compounds of four ingredients of AYUSH-64 screened, 35 exhibited good binding energies to the main protease with the best affinity and interactions seen with Akuammicine N-Oxide (from A. scholaris) [20].

Clinical trials of different AYUSH medicines like Ashwagandha, Yashthimadhu, Guduchi, Pippali on patients, health workers, and those working in high-risk areas were also initiated by the Ministry of AYUSH. In silico network pharmacology and docking studies carried out to explore the immunomodulatory and anti SARS-CoV2 potential of phytoconstituents from Ashwagandha, Guduchi and Shatavari against the Spike protein, Main Protease and RNA dependent RNA polymerase of the virus. The results showed that these phytoconstituents possessed good affinity for the three targets, suggesting their application for the termination of viral life cycle [21].

Different ayurvedic proprietary medicines like ZINGIVIR-H, Aayush Advance/Purified aqueous extract of C. hirsutus (AQCH), a phytopharmaceutical, Amta karuna syrup, Virulina®, Astha-15, were also shown to be effective in improving the clinical condition of Covid19 patients when given as add-on therapy through their immunomodulatory properties [22].

One of the limitations of our study was that the clinical symptoms were measured as ordinal data (Present/Absent) rather than using a VAS scale. This was done mainly to minimize the stress on the patients as initially many of them were on oxygen supplementation and also to restrict the length of contact between the patient and the study team member due to the Covid positive status of the patients.

8. Conclusion

Thus, the results of the randomized, comparative controlled clinical study assessing the efficacy of a combination of Cap. Torchnil and Tab. Febcin in patients with moderate Covid-19 disease showed that these two formulations were effective when given as add-on therapy to standard of care. The formulations hastened clinical recovery, viral clearance, decreased oxygen requirements and lowered inflammatory biomarker levels suggesting that they have a role in the clinical management of Covid-19 patients with moderate disease.

Source(s) of funding

Dr. Palep's House of Health & Medical Research Foundation Pvt. Ltd, Mumbai.

Author contributions

RM: Conceptualization, Methodology/Study design, Validation, Formal analysis, Investigation, resources, Data curation, Writing — original draft, Writing — review and editing, Visualization, Supervision, Project administration. DK: Methodology/Study design, Formal analysis, Investigation, resources, Data curation, Writing — original draft, Writing — review and editing, Supervision, Project administration. PP: Conceptualization, Methodology/Study design, Formal analysis, Investigation, resources, Data curation, Supervision, Project administration. GR: Conceptualization, Methodology/Study design, Formal analysis, Resources, Data curation, Supervision, Project administration, HSP: Conceptualization, Methodology/Study design, Resources, Writing — review and editing, Visualization, Supervision, Funding acquisition.

Conflict of interest

None.
Acknowledgment

The Authors wish to acknowledge the support given by Dr. Rumana Ansari and Dr. Prerna Hosmani for the recruitment and follow up of the study patients.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jaim.2022.100559.